In an attempt to achieve dual-target, Huang and coworkers developed CD133 and CD44 aptamer-conjugated nanomicelles loaded with gefitinib (CD133/CD44-NM-Gef) that were capable of simultaneous targeting to CD44+ and CD133+ lung cancer-initiating cells. The gene discussed is PROM1; the disease is lung carcinoma.